ADMA Biologics vs Kamada
ADMA and KMDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADMA and KMDA compare
Kamada grew revenue faster over the last twelve months (13.2% versus 6.3% for ADMA Biologics).
ADMA Biologics scores higher on the StockData Score (16 against 5 for Kamada), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADMA | KMDA |
|---|---|---|
| Size and price | ||
| Market cap | $3.0B | – |
| Share price | $13.24 | $8.13 |
| Change, 1 year | −17.4% | 15.2% |
| Change, 5 years | 765% | 45.2% |
| Beta (5Y) | 0.64 | 0.76 |
| Employees | 647 | 393 |
| StockData Score | ||
| Total score | 16 (better) | 5 |
| Valuation score | 5 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 4 (better) | 0 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 17.2× | – |
| P/S | 5.7× | – |
| P/B | 6.8× | – |
| EV/EBITDA | 12.2× | – |
| P/FCF | 22.3× | – |
| FCF yield | 4.5% | – |
| Fair value | $21.15 | – |
| Margin of safety | 37.4% | – |
| Growth | ||
| Revenue growth (TTM) | 6.3% | 13.2% (better) |
| Revenue growth, 5Y average | 64.6% (better) | 6.3% |
| Net income growth (TTM) | −12.9% | – |
| EPS growth (TTM) | −9.4% | – |
| EPS growth, 5Y average | – | −1.6% |
| Profitability | ||
| Gross margin | 68.5% (better) | 40.8% |
| Operating margin | 46.5% (better) | 14.5% |
| Net margin | 35.1% | – |
| FCF margin | 25.6% | – |
| Return on equity | 41.9% | – |
| Return on invested capital | 39.4% | – |
| Financial health | ||
| Debt / equity | 0.45 | – |
| Net debt / EBITDA | 0.29 (better) | −0.54 |
| Interest coverage | 22.8× | 26.8× (better) |
| Current ratio | 6.04 (better) | 4.06 |
| Altman Z-score | 8.58 | – |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Buyback yield | 6.4% | – |
| Shareholder yield | 6.4% | – |
| Ownership | ||
| Held by institutions | 91.8% | 8.6% |
| Held by insiders | 3.0% | 45.3% |
| Insider net buying, 12 months | −$2.5M | −$1.7M (better) |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 8.3% | 0.53% |
Go deeper
- ADMA stock overview
- ADMA income statement
- ADMA valuation and score
- KMDA stock overview
- KMDA income statement
- KMDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.